1
|
Kenny G, O'Reilly S, Wrigley Kelly N, Negi R, Gaillard C, Alalwan D, Saini G, Alrawahneh T, Francois N, Angeliadis M, Garcia Leon AA, Tinago W, Feeney ER, Cotter AG, de Barra E, Yousif O, Horgan M, Doran P, Stemler J, Koehler P, Cox RJ, O'Shea D, Olesen OF, Landay A, Hogan AE, Lelievre JD, Gautier V, Cornely OA, Mallon PWG. Distinct receptor binding domain IgG thresholds predict protective host immunity across SARS-CoV-2 variants and time. Nat Commun 2023; 14:7015. [PMID: 37919289 PMCID: PMC10622572 DOI: 10.1038/s41467-023-42717-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2022] [Accepted: 10/19/2023] [Indexed: 11/04/2023] Open
Abstract
SARS-CoV-2 neutralising antibodies provide protection against COVID-19. Evidence from early vaccine trials suggested binding antibody thresholds could serve as surrogate markers of neutralising capacity, but whether these thresholds predict sufficient neutralising capacity against variants of concern (VOCs), and whether this is impacted by vaccine or infection history remains unclear. Here we analyse individuals recovered from, vaccinated or with hybrid immunity against SARS-CoV-2. An NT50 ≥ 100 IU confers protection in vaccine trials, however, as VOC induce a reduction in NT50, we use NT50 ≥ 1000 IU as a cut off for WT NT50 that would retain neutralisation against VOC. In unvaccinated convalescent participants, a receptor binding domain (RBD) IgG of 456 BAU/mL predicts an NT50 against WT of 1000 IU with an accuracy of 80% (95%CI 73-86%). This threshold maintains accuracy in determining loss of protective immunity against VOC in two vaccinated cohorts. It predicts an NT50 < 100 IU against Beta with an accuracy of 80% (95%CI 67-89%) in 2 vaccine dose recipients. In booster vaccine recipients with a history of COVID-19 (hybrid immunity), accuracy is 87% (95%CI 77-94%) in determining an NT50 of <100 IU against BA.5. This analysis provides a discrete threshold that could be used in future clinical studies.
Collapse
Affiliation(s)
- Grace Kenny
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland.
| | - Sophie O'Reilly
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Neil Wrigley Kelly
- St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
- Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland
| | - Riya Negi
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Colette Gaillard
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Dana Alalwan
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Gurvin Saini
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Tamara Alrawahneh
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Nathan Francois
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Matthew Angeliadis
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Alejandro Abner Garcia Leon
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Willard Tinago
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Eoin R Feeney
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
- St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
| | - Aoife G Cotter
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
- Department of Infectious Diseases, Mater Misericordiae University Hospital, Eccles St, Dublin 7, Ireland
| | - Eoghan de Barra
- Department of Infectious Diseases, Beaumont Hospital, Beaumont, Dublin 9, Ireland
- Department of International Health and Tropical Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
| | - Obada Yousif
- Endocrinology Department, Wexford General Hospital, Carricklawn, Wexford, Ireland
| | - Mary Horgan
- Department of Infectious Diseases, Cork University Hospital, Wilton, Co Cork, Ireland
| | - Peter Doran
- School of Medicine, University College Dublin, Belfield, Dublin 4, Ireland
| | - Jannik Stemler
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Internal Medicine and University of Cologne, Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne Department Cologne, Cologne, Germany
| | - Philipp Koehler
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Internal Medicine and University of Cologne, Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne Department Cologne, Cologne, Germany
| | - Rebecca Jane Cox
- Influenza Centre, Department of Clinical Science, University of Bergen, Bergen, Norway
| | - Donal O'Shea
- St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
| | - Ole F Olesen
- European Vaccine Initiative, Heidelberg, Germany
| | - Alan Landay
- Department of internal Medicine, Rush University, Chicago, IL, USA
| | - Andrew E Hogan
- Kathleen Lonsdale Institute for Human Health Research, Maynooth University, Maynooth, Co Kildare, Ireland
- National Children's Research Centre, Dublin 12, Ireland
| | | | - Virginie Gautier
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
| | - Oliver A Cornely
- University of Cologne, Faculty of Medicine and University Hospital Cologne, Department of Internal Medicine and University of Cologne, Faculty of Medicine Institute of Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany
- German Centre for Infection Research (DZIF), Partner Site Bonn-Cologne Department Cologne, Cologne, Germany
| | - Patrick W G Mallon
- Centre for Experimental Pathogen Host Research (CEPHR), University College Dublin, Belfield, Dublin 4, Ireland
- St Vincent's University Hospital, Elm Park, Dublin 4, Ireland
| |
Collapse
|
2
|
Khosroshahi ME, Patel Y. Reflective FT-NIR and SERS studies of HER-II breast cancer biomarker using plasmonic-active nanostructured thin film immobilized oriented antibody. JOURNAL OF BIOPHOTONICS 2023; 16:e202200252. [PMID: 36177970 DOI: 10.1002/jbio.202200252] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Revised: 09/12/2022] [Accepted: 09/23/2022] [Indexed: 06/16/2023]
Abstract
We describe the fabrication of plasmonic-active nanostructured thin film substrate as a label-free surface-enhanced Raman scattering (SERS)-based biosensor immobilized covalently with monoclonal HER-II antibody (mAb) to detect overexpressed HER-II as a biomarker in breast cancer serum (BCS). Oriented conjugation of mAb via hydrazone linkage to provide higher mAb accessibility was characterized by UV-vis and reflective Fourier transform near-infrared (FT-NIR) spectroscopic techniques. The interaction of BCS with mAb was studied by FT-NIR and nonresonant SERS at 637 nm. The results showed detection of glycoprotein content at different laser powers including a rise in amino acid and glycan content with varying results at higher power. With nonresonant SERS we observed nonlinear behavior of peak intensity. Analysis of variance was implemented to determine the effect of laser power which was found not to be a contributing factor. However, at the nanoscale, factors including the heating effect and aggregation of molecules can contribute to the nonlinearity of peak intensity.
Collapse
Affiliation(s)
- Mohammad E Khosroshahi
- Nanobiophotonics and Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, Ontario, Canada
- Institute for Advanced Non-Destructive & Diagnostic Technologies (IANDIT), University of Toronto, Toronto, Ontario, Canada
| | - Yesha Patel
- Nanobiophotonics and Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, Ontario, Canada
- Department of Biochemistry, University of Waterloo, Waterloo, Ontario, Canada
| |
Collapse
|
3
|
Khosroshahi ME, Patel Y, Chabok R. Non-invasive optical characterization and detection of CA 15-3 breast cancer biomarker in blood serum using monoclonal antibody-conjugated gold nanourchin and surface-enhanced Raman scattering. Lasers Med Sci 2022; 38:24. [PMID: 36571665 DOI: 10.1007/s10103-022-03675-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2022] [Accepted: 10/22/2022] [Indexed: 12/27/2022]
Abstract
A proof-of-concept of colloidal surface-enhanced Raman scattering (SERS) substrate for rapid selective detection of overexpressed CA 15-3 biomarker in breast cancer serum (BCS) is suggested using PEGylated gold nanourchins (GNUs) conjugated with anti-CA 15-3 monoclonal antibody (mAb). UV-vis spectroscopy provided conformational information about mAb where the initial aromatic amino acid peak was red-shifted from 271 to 291 nm. The fluorescence peak of tyrosine in mAb was reduced by ≈ 77%, and red-shifted by ≈ 3 nm after incubation in BCS. Fourier transform near-infrared spectroscopy and SERS were used to study the composition and the molecular structure of the mAb and BCS. Some of the most dominant Raman shifts after GNU-PEG-mAb interaction with BCS are 498, 736, 818, 1397, 1484, 2028, 2271, and 3227 cm-1 mainly corresponding to C-N-C in amines, vibrational modes of amino acids, C-H out-of-plane bend, C-O stretching carboxylic acid, the vibrational mode in phospholipids, NH3+ amine salt, C≡N stretching in nitriles, and O-H stretching. The intensity of SERS signals varied per trial due to the statistical behavior of GNU in BCS, agglomeration, laser power, and the heating effect. Despite very small amount of plasmonic heating, the result of the ANOVA test demonstrated that under our experimental conditions, the heating effect on signal variation is negligible and that the differences in the laser power are insignificant for all SERS observations (p > 0.6); thus, other parameters are responsible. The absorbance of mAb-conjugated GNU was decreased after five minutes of irradiation at 8 mW in the BCS.
Collapse
Affiliation(s)
- Mohammad E Khosroshahi
- Nanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON, L4B 1B4, Canada.
- Institute for Advanced Non-Destructive & Diagnostic Technologies (IANDIT), University of Toronto, Toronto, M5S 3G8, Canada.
| | - Yesha Patel
- Nanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON, L4B 1B4, Canada
- Department of Biochemistry, Faculty of Science, University of Waterloo, Waterloo, N2L 3G1, Canada
| | - Roxana Chabok
- Nanobiophotonics & Biomedical Research Laboratory, M.I.S. Electronics Inc., Richmond Hill, ON, L4B 1B4, Canada
- Department of Chemical Engineering, Faculty of Engineering, University of Waterloo, Waterloo, N2L 3G1, Canada
| |
Collapse
|
4
|
Ambade V, Singh A, Bhatia K, Misra P, Mukherjee B, Negi R. Serum tumor markers: A study on their rational use in various cancers. MEDICAL JOURNAL OF DR. D.Y. PATIL VIDYAPEETH 2022. [DOI: 10.4103/mjdrdypu.mjdrdypu_175_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
|
5
|
Cheng KL, Huang YK. Pyogenic liver abscesses with an elevated carcinoembryonic antigen level. J Med Ultrasound 2022; 30:226-228. [DOI: 10.4103/jmu.jmu_145_21] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Revised: 08/25/2021] [Accepted: 09/03/2021] [Indexed: 11/04/2022] Open
|
6
|
Japp NC, Souchek JJ, Sasson AR, Hollingsworth MA, Batra SK, Junker WM. Tumor Biomarker In-Solution Quantification, Standard Production, and Multiplex Detection. J Immunol Res 2021; 2021:9942605. [PMID: 34514003 PMCID: PMC8426080 DOI: 10.1155/2021/9942605] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Accepted: 08/13/2021] [Indexed: 12/12/2022] Open
Abstract
The diagnosis and monitoring of cancer have been facilitated by discovering tumor "biomarkers" and methods to detect their presence. Yet, for certain cancers, we still lack sensitive and specific biomarkers or the means to quantify subtle concentration changes successfully. The identification of new biomarkers of disease and improving the sensitivity of detection will remain key to changing clinical outcomes. Patient liquid biopsies (serum and plasma) are the most easily obtained sources for noninvasive analysis of proteins that tumor cells release directly and via extracellular microvesicles and tumor shedding. Therefore, an emphasis on creating reliable assays using serum/plasma and "direct, in-solution" ELISA approaches has built an industry centered on patient protein biomarker analysis. A need for improved dynamic range and automation has resulted in the application of ELISA principles to paramagnetic beads with chemiluminescent or fluorescent detection. In the clinical testing lab, chemiluminescent paramagnetic assays are run on automated machines that test a single analyte, minimize technical variation, and are not limited by serum sample volumes. This differs slightly from the R&D setting, where serum samples are often limiting; therefore, multiplexing antibodies to test multiple biomarkers in low serum volumes may be preferred. This review summarizes the development of historical biomarker "standards", paramagnetic particle assay principles, chemiluminescent or fluorescent biomarker detection advancements, and multiplexing for sensitive detection of novel serum biomarkers.
Collapse
Affiliation(s)
- Nicole C. Japp
- Sanguine Diagnostics and Therapeutics, Inc., Omaha, Nebraska, USA
| | | | - Aaron R. Sasson
- Sanguine Diagnostics and Therapeutics, Inc., Omaha, Nebraska, USA
- Department of Surgery, Renaissance School of Medicine, Stony Brook University, Stony Brook, New York, USA
| | - Michael A. Hollingsworth
- Sanguine Diagnostics and Therapeutics, Inc., Omaha, Nebraska, USA
- Eppley Institute for Research in Cancer & Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Surinder K. Batra
- Sanguine Diagnostics and Therapeutics, Inc., Omaha, Nebraska, USA
- Eppley Institute for Research in Cancer & Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska, USA
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| | - Wade M. Junker
- Sanguine Diagnostics and Therapeutics, Inc., Omaha, Nebraska, USA
- Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, Nebraska, USA
| |
Collapse
|
7
|
Sarogni P, Mapanao AK, Marchetti S, Kusmic C, Voliani V. A Standard Protocol for the Production and Bioevaluation of Ethical In Vivo Models of HPV-Negative Head and Neck Squamous Cell Carcinoma. ACS Pharmacol Transl Sci 2021; 4:1227-1234. [PMID: 34151212 PMCID: PMC8205242 DOI: 10.1021/acsptsci.1c00083] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2021] [Indexed: 11/29/2022]
Abstract
Preclinical cancer research increasingly demands sophisticated models for the development and translation of efficient and safe cancer treatments to clinical practice. In this regard, tumor-grafted chorioallantoic membrane (CAM) models are biological platforms that account for the dynamic roles of the tumor microenvironment and cancer physiopathology, allowing straightforward investigations in agreement to the 3Rs concept (the concept of reduction, refinement, and replacement of animal models). CAM models are the next advanced model for tumor biological explorations as well as for reliable assessment regarding initial efficacy, toxicity, and systemic biokinetics of conventional and emerging neoplasm treatment modalities. Here we report a standardized and optimized protocol for the production and biocharacterization of human papillomavirus (HPV)-negative head and neck chick chorioallantoic membrane models from a commercial cell line (SCC-25). Oral malignancies continue to have severe morbidity with less than 50% long-term survival despite the advancement in the available therapies. Thus, there is a persisting demand for new management approaches to establish more efficient strategies toward their treatment. Remarkably, the inclusion of CAM models in the preclinical research workflow is crucial to ethically foster both the basic and translational oncological research on oral malignancies as well as for the advancement of efficient cancer treatment approaches.
Collapse
Affiliation(s)
- Patrizia Sarogni
- Center
for Nanotechnology Innovation@NEST, Istituto
Italiano di Tecnologia, Piazza San Silvestro 12, Pisa 56126, Italy
| | - Ana Katrina Mapanao
- Center
for Nanotechnology Innovation@NEST, Istituto
Italiano di Tecnologia, Piazza San Silvestro 12, Pisa 56126, Italy
- NEST-Scuola
Normale Superiore, Piazza
San Silvestro 12, Pisa 56126, Italy
| | - Sabrina Marchetti
- Institute
of Clinical Physiology, CNR, Via G. Moruzzi 1, Pisa 56100, Italy
| | - Claudia Kusmic
- Institute
of Clinical Physiology, CNR, Via G. Moruzzi 1, Pisa 56100, Italy
| | - Valerio Voliani
- Center
for Nanotechnology Innovation@NEST, Istituto
Italiano di Tecnologia, Piazza San Silvestro 12, Pisa 56126, Italy
| |
Collapse
|
8
|
Yang W, Luo Y, Hu S, Li Y, Liu Q. Value of combined detection of serum carcino-embryonic antigen, carbohydrate antigen 19-9 and cyclooxygenase-2 in the diagnosis of colorectal cancer. Oncol Lett 2018; 16:1551-1556. [PMID: 30008836 PMCID: PMC6036331 DOI: 10.3892/ol.2018.8792] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2017] [Accepted: 05/18/2018] [Indexed: 12/22/2022] Open
Abstract
The aim of the present study was to investigate the value of combined detection of serum carcino-embryonic antigen (CEA), carbohydrate antigen (CA) 19-9 and cyclooxygenase-2 (COX-2) in the diagnosis of colorectal cancer. A total of 50 patients with colorectal cancer were selected as Group A and 50 healthy subjects as the control group. A sample of 2 ml fasting venous blood was drawn from patients in each group, and serum CEA, CA19-9 and COX-2 were detected using electrochemiluminescence analyzer and ELISA. Receiver operating characteristic curve analysis was performed on analyze the sensitivity and specificity of diagnostic methods for colorectal cancer patients at different stages. The expression levels of CEA, CA199 and COX-2 in the cancer patients group were significantly higher than those in the healthy group (P<0.05). The coincidence rates of CEA, CA199, COX-2 and combined detection were 56.0, 64.0, 62.0 and 88.0%, respectively. The coincidence rate of combined detection was significantly higher than that of diagnosis using a single factor (P<0.05). Sensitivity of combined detection of colorectal cancer patients with stage I, II, III and IV were 82.9, 85.3, 86.4 and 88.7%, respectively. The specificities were 65.3, 68.7, 57.8 and 58.6%, respectively. Thus, CEA, CA199 and COX-2 in serum are highly expressed in colorectal cancer patients, and may useful as effective indicators for the early diagnosis of colorectal cancer.
Collapse
Affiliation(s)
- Weili Yang
- Department of Gastroenterology, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518000, P.R. China
| | - Yongsheng Luo
- Department of Gastroenterology, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518000, P.R. China
| | - Shuangcheng Hu
- Department of Gastroenterology, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518000, P.R. China
| | - Ying Li
- Department of Gastroenterology, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518000, P.R. China
| | - Qing Liu
- Department of Gastroenterology, The Second People's Hospital of Shenzhen, Shenzhen, Guangdong 518000, P.R. China
| |
Collapse
|
9
|
Abdul Hameed AM, Abdul Hamid AF, Noor NS, Appalanaido GK, Sahul Hamid SB. Study on IL-2 and CA 15-3 level as combined biomarkers in monitoring chemotherapeutic response among invasive breast cancer patients. ACTA ACUST UNITED AC 2017. [DOI: 10.1088/1742-6596/851/1/012038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
10
|
Liu F, Tian T, Xia LL, Ding Y, Cormier RT, He Y. Circulating miRNAs as novel potential biomarkers for esophageal squamous cell carcinoma diagnosis: a meta-analysis update. Dis Esophagus 2017; 30:1-9. [PMID: 27003597 DOI: 10.1111/dote.12489] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Early detection of esophageal squamous cell carcinoma (ESCC) is urgently needed to reduce the high morbidity and mortality of disease. Circulating microRNAs (miRNAs) are promising molecular biomarkers for ESCC prediction. We performed a comprehensive meta-analysis to systematically evaluate the diagnostic accuracy of circulating miRNAs in diagnosis of ESCC patients. Eligible studies were identified and assessed for quality employing multiple search strategies. Summary estimates for sensitivity, specificity, and other measures of accuracy of miRNAs in the diagnosis of ESCC were pooled using the bivariate random effects model. A total of 27 studies from 11 published articles were included in the meta-analysis. The overall sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating miRNAs for the diagnosis of ESCC were 79.9% (95% confidence intervals [CI]: 76.2%-83.1%), 81.3% (95% CI: 75.7-85.9), 4.27 (95%CI: 3.27-5.58), 0.25 (95% CI: 0.21-0.29), and 17.29 (95% CI: 12.01-24.86), respectively. The area under the summary receiver operating characteristic curve was 0.87 (95% CI: 0.84-0.90). The subgroup analyses based on research country (China vs. Japan), specimen type (plasma vs. serum), miRNAs profiling (single vs. multiple), and test method (screening vs. candidate; Taqman vs. SYBR) indicated no significant difference in the diagnostic accuracy of each subgroup. Collectively, our findings indicate that circulating miRNAs have significant potential to be used as noninvasive biomarkers for early detection of ESCC. Moreover, the subgroup analyses demonstrated the feasibility of using blood miRNAs as an ESCC diagnostic biomarker in Japanese and Chinese populations. Further, both plasma and serum are recommended as clinical specimens for miRNA detection. Further studies will be needed to validate these findings using larger numbers of patients.
Collapse
Affiliation(s)
- Fen Liu
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China.,Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China
| | - Tian Tian
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China.,Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Institute of Reproductive & Child Health, Peking University, Beijing, China
| | - Li-Li Xia
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China.,Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China
| | - Yuanjie Ding
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China.,Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China
| | - Robert T Cormier
- Department of Biomedical Sciences, University of Minnesota Medical School Duluth, Duluth, Minnesota, USA
| | - Yan He
- Department of Epidemiology and Health Statistics, School of Public Health, Capital Medical University, Beijing, China.,Beijing Municipal Key Laboratory of Clinical Epidemiology, Beijing, China
| |
Collapse
|
11
|
Ding Y, Ma Q, Liu F, Zhao L, Wei W. The Potential Use of Salivary miRNAs as Promising Biomarkers for Detection of Cancer: A Meta-Analysis. PLoS One 2016; 11:e0166303. [PMID: 27832115 PMCID: PMC5104484 DOI: 10.1371/journal.pone.0166303] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2016] [Accepted: 10/26/2016] [Indexed: 12/19/2022] Open
Abstract
BACKGROUND Accumulating evidence has demonstrated that microRNAs (miRNAs) could serve as promising molecular biomarkers for cancer detection. This study aims to systematically assess the diagnostic performance of salivary miRNAs in detection of cancer through a comprehensive meta-analysis. METHODS Eligible studies were identified using PubMed and other computerized databases up to October 31, 2015, supplemented by a manual search of references from retrieved articles. The pooled sensitivity, specificity, and other measurements of accuracy of salivary miRNAs in the diagnosis of cancer were analyzed using the bivariate binomial mixed model. RESULTS Seventeen studies from 8 articles with 694 subjects were included in this meta-analysis. All studies have a relatively high score of quality assessment. The overall sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), and diagnostic odds ratio (DOR) of salivary miRNAs in detection of cancer were 0.77 (95% confidence intervals [CI]: 0.69-0.84), 0.77 (95%CI: 0.65-0.88), 3.37 (95%CI: 2.26-5.02), 0.29 (95%CI: 0.23-0.38), and 11.41 (95%CI: 7.35-17.73), respectively. The AUC was 0.84 (95%CI: 0.80-0.87). Moreover, both whole saliva and saliva supernatant could be used as sources of clinical specimens for miRNAs detection. CONCLUSIONS Our meta-analysis demonstrated that salivary miRNAs may serve as potential noninvasive biomarkers for cancer detection. The findings need to be confirmed with further research before it can be applied in the clinic.
Collapse
Affiliation(s)
- Yuanjie Ding
- Department of Epidemiology and Health Statistics, School of Public Health, Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, China
| | - Qing Ma
- Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
| | - Fen Liu
- Department of Epidemiology and Health Statistics, School of Public Health, Beijing Municipal Key Laboratory of Clinical Epidemiology, Capital Medical University, Beijing, China
- * E-mail: (FL); (WW)
| | - Lei Zhao
- Department of Molecular Physiology and Biophysics, Holden Comprehensive Cancer Center, University of Iowa Carver College of Medicine, Iowa City, IA, United States of America
| | - Wenqiang Wei
- Department of Cancer Epidemiology, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China
- * E-mail: (FL); (WW)
| |
Collapse
|
12
|
Tariba B, Živković T, Filipović Marijić V, Erk M, Gamulin M, Pizent A. Does the Serum Metallothionein Level Reflect the Stage of Testicular Germ Cell Tumor? Arch Med Res 2016; 47:232-5. [PMID: 27255355 DOI: 10.1016/j.arcmed.2016.05.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Accepted: 05/20/2016] [Indexed: 10/21/2022]
Abstract
Increased levels of metallothionein (MT) have recently been found in the blood serum of men with newly diagnosed testicular germ cell tumors (TGCT). In light of previously published results, the aim of this study was to investigate the difference in serum MT levels among patients with different stages of TGCT and compare MT with commonly used markers (α-fetoprotein, β-human chorionic gonadotropin and lactate dehydrogenase). The concentration of total MT was determined in the serum of 25 men with TGCT (seminoma or non-seminoma) by differential pulse voltammetry. Serum samples were obtained prior to chemotherapy, after two cycles of chemotherapy and 1 year after chemotherapy. A statistically significant difference in MT levels in patients with different stages of TGCT was observed in the serum of patients with non-seminoma obtained before chemotherapy. Although not significant, an increase in serum MT levels commensurate with the disease stage increase was also observed in patients with seminomatous TGCT. The results indicate that, in combination with the existing markers, MT could be useful for the identification of the histological type of tumor and stage of the disease before biopsy diagnosis.
Collapse
Affiliation(s)
- Blanka Tariba
- Analytical Toxicology and Mineral Metabolism Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia.
| | - Tanja Živković
- Analytical Toxicology and Mineral Metabolism Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia
| | - Vlatka Filipović Marijić
- Laboratory for Biological Effects of Metals, Division for Marine and Environmental Research, Ruđer Bošković Institute, Zagreb, Croatia
| | - Marijana Erk
- Laboratory for Biological Effects of Metals, Division for Marine and Environmental Research, Ruđer Bošković Institute, Zagreb, Croatia
| | - Marija Gamulin
- Department of Oncology, University Hospital Centre Zagreb, Zagreb, Croatia
| | - Alica Pizent
- Analytical Toxicology and Mineral Metabolism Unit, Institute for Medical Research and Occupational Health, Zagreb, Croatia
| |
Collapse
|
13
|
Barlev E, Zelig U, Bar O, Segev C, Mordechai S, Kapelushnik J, Nathan I, Flomen F, Kashtan H, Dickman R, Madhala-Givon O, Wasserberg N. A novel method for screening colorectal cancer by infrared spectroscopy of peripheral blood mononuclear cells and plasma. J Gastroenterol 2016; 51:214-21. [PMID: 26112122 DOI: 10.1007/s00535-015-1095-7] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/23/2015] [Accepted: 06/04/2015] [Indexed: 02/04/2023]
Abstract
BACKGROUND Early detection of colorectal cancer (CRC) can reduce mortality and morbidity. Current screening methods include colonoscopy and stool tests, but a simple low-cost blood test would increase compliance. This preliminary study assessed the utility of analyzing the entire bio-molecular profile of peripheral blood mononuclear cells (PBMCs) and plasma using Fourier transform infrared (FTIR) spectroscopy for early detection of CRC. METHODS Blood samples were prospectively collected from 62 candidates for CRC screening/diagnostic colonoscopy or surgery for colonic neoplasia. PBMCs and plasma were separated by Ficoll gradient, dried on zinc selenide slides, and placed under a FTIR microscope. FTIR spectra were analyzed for biomarkers and classified by principal component and discriminant analyses. Findings were compared among diagnostic groups. RESULTS Significant changes in multiple bands that can serve as CRC biomarkers were observed in PBMCs (p = ~0.01) and plasma (p = ~0.0001) spectra. There were minor but statistically significant differences in both blood components between healthy individuals and patients with benign polyps. Following multivariate analysis, the healthy individuals could be well distinguished from patients with CRC, and the patients with benign polyps were mostly distributed as a distinct subgroup within the overlap region. Leave-one-out cross-validation for evaluating method performance yielded an area under the receiver operating characteristics curve of 0.77, with sensitivity 81.5% and specificity 71.4%. CONCLUSIONS Joint analysis of the biochemical profile of two blood components rather than a single biomarker is a promising strategy for early detection of CRC. Additional studies are required to validate our preliminary clinical results.
Collapse
Affiliation(s)
- Eyal Barlev
- Department of Surgery B, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Udi Zelig
- Todos Medical Ltd, 1 HaMada St, 76703, Rehovot, Israel.
| | - Omri Bar
- Todos Medical Ltd, 1 HaMada St, 76703, Rehovot, Israel
| | - Cheli Segev
- Todos Medical Ltd, 1 HaMada St, 76703, Rehovot, Israel
| | - Shaul Mordechai
- Department of Physics, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Joseph Kapelushnik
- Pediatric Hemato-Oncology Unit, Soroka University Medical Center, Beer-Sheva, Israel
- Faculty of Medicine, Ben-Gurion University of the Negev, Beer-Sheva, Israel
| | - Ilana Nathan
- Department of Clinical Biochemistry, Ben-Gurion University of the Negev, Beer-Sheva, Israel
- Institute of Hematology, Soroka University Medical Center, Beer-Sheva, Israel
| | - Felix Flomen
- Todos Medical Ltd, 1 HaMada St, 76703, Rehovot, Israel
| | - Hanoch Kashtan
- Division of General Surgery, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
| | - Ram Dickman
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
- Department of Gastroenterology, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
| | - Osnat Madhala-Givon
- Department of Surgery B, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| | - Nir Wasserberg
- Department of Surgery B, Rabin Medical Center, Beilinson Campus, Petach Tikva, Israel
- Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
| |
Collapse
|
14
|
Tumour markers and kidney function: a systematic review. BIOMED RESEARCH INTERNATIONAL 2014; 2014:647541. [PMID: 24689048 PMCID: PMC3933284 DOI: 10.1155/2014/647541] [Citation(s) in RCA: 37] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 08/16/2013] [Revised: 12/02/2013] [Accepted: 12/06/2013] [Indexed: 01/18/2023]
Abstract
Tumour markers represent useful tools in diagnosis and clinical management of patients with cancer, because they are easy to use, minimally invasive, and easily measured in either blood or urine. Unfortunately, such an ideal marker, as yet, does not exist. Different pathological states may increase the level of a tumour marker in the absence of any neoplasia. Alternatively, low levels of tumour markers could be also found in the presence of neoplasias. We aimed at reviewing studies currently available in the literature examining the association between tumour markers and different renal impairment conditions. Each tumour marker was found to be differently influenced by these criteria; additionally we revealed in many cases a lack of available published data.
Collapse
|
15
|
Wang TC, Song YS, Yu SF, Zhang J, Wang H, Gu YE, Chen T, Jia G. Association of folate deficiency and selected tumor marker concentrations in long-term hexavalent chromium exposed population. Int J Hyg Environ Health 2014; 217:88-94. [DOI: 10.1016/j.ijheh.2013.03.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2012] [Revised: 03/23/2013] [Accepted: 03/25/2013] [Indexed: 10/27/2022]
|
16
|
Ostrovsky E, Zelig U, Gusakova I, Ariad S, Mordechai S, Nisky I, Kapilushnik J. Detection of cancer using advanced computerized analysis of infrared spectra of peripheral blood. IEEE Trans Biomed Eng 2012. [PMID: 23193226 DOI: 10.1109/tbme.2012.2226882] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
We have developed a novel approach for detection of cancer based on biochemical analysis of peripheral blood plasma using Fourier transform infrared spectroscopy. This approach has proven to be quick, safe, minimal invasive, and effective. Our approach recognizes any signs of solid tumor presence, regardless of location in the body or cancer type by measuring a spectrum that gives information regarding the total molecular composition and structure of the peripheral blood samples. The analysis includes clinically relevant preprocessing and feature extraction with principal component analysis, and uses Fisher's linear discriminant analysis to classify between cancer patients and healthy controls. We evaluated our method with leave-one-out cross validation and were able to establish sensitivity of 93.33%, specificity of 87.8%, and overall accuracy of 90.7%. Using our method for cancer detection should result in fewer unnecessary invasive procedures and yield fast detection of solid tumors.
Collapse
Affiliation(s)
- Ela Ostrovsky
- Department of Biomedical Engineering, Ben-Gurion University of the Negev, Beer Sheva 84105, Israel.
| | | | | | | | | | | | | |
Collapse
|